

[Revision log](#)
[Coding Implications](#)

CONCERT GENETIC TESTING: HEMATOLOGY

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

OVERVIEW

This policy addresses the use of diagnostic tests for benign (non-cancerous) hematologic conditions.

For additional information see the [Rationale](#) section.

POLICY REFERENCE TABLE

Coding Implications

This clinical policy references Current Procedural Terminology (CPT[®]). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

The tests, CPT codes, and ICD codes referenced in this policy are not comprehensive, and their inclusion does not represent a guarantee of coverage or non-coverage. Please see the [Concert Platform](#) for additional registered tests.

CRITERIA SECTIONS	EXAMPLE TESTS (LABS)	COMMON BILLING CODES	REF
Inherited Thrombophilia			

Factor V Leiden (F5) and Prothrombin (F2) Variant Analysis for Inherited Thrombophilia	Factor V (Leiden) Mutation Analysis (Quest Diagnostics) Prothrombin (Factor II) 20210G>A Mutation Analysis (Quest Diagnostics)	81240, 81241, D68.2, D68.51, D68.59, I82.90, R79.1, Z86.2	1, 5
Hemoglobinopathies			
HBA1/HBA2 and/or HBB Variant Analysis	Alpha Thalassemia Panel (Prevention Genetics, part of Exact Sciences) Alpha-Globin Common Mutation Analysis (Quest Diagnostics) Beta Globin (HBB) Sequencing (ARUP Laboratories) Beta Globin Gene Dosage Analysis (Quest Diagnostics)	81257, 81259, 81269, 81363, 81364, D53.9, D56.0, D56.1, D56.3, D56.8, D56.9, D57, D64.9, R70.1, Z86.2	2, 3, 4, 6
Hemophilia			
Factor VIII (F8) and Factor IX (F9) Variant Analysis for Hemophilia A and B	Factor VIII (Hemophilia A) Genetic Analysis (Labcorp) Factor IX (Hemophilia B) Genetic Analysis (Labcorp)	81238, 81403, 81406, 81407, D66, D67, I62.9, M25, N92.2, R04.0, R31	7, 8
von Willebrand Disease			
VWF Variant Analysis	Von Willebrand Disease Gene Sequencing (Quest)	81408, 81479, D68.0	9
Fanconi Anemia			
Fanconi Anemia Multigene Panel	FancZoom (DNA Diagnostic Laboratory - Johns Hopkins Hospital)	81162, 81307, 81479, C92, D46.9, D61.09, D61.89, D61.9, L81.3, L81.4 Q02, R62.52	13, 14

<u>Other Covered Hematologic Conditions (non-cancerous)</u>			
<u>Other Covered Hematologic Conditions (non-cancerous)</u>	See list below	81400, 81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408	10, 11, 12

RELATED POLICIES

This policy document provides criteria for benign (non-cancerous) hematologic conditions. Please refer to:

- ***Oncology Testing: Solid Tumor Molecular Diagnostics*** for criteria related to molecular profiling of a known or suspected cancer (e.g. broad molecular profiling, including Minimal Residual Disease (MRD) Testing, Tumor Mutational Burden (TMB), and cytogenetic / fusion testing).
- ***Specialty Testing: Nutrition and Metabolism*** for criteria related to diagnostic and serum biomarker tests for nutritional status and biochemical disorders.
- ***General Approach to Laboratory Testing*** for criteria related to genetic testing for non-cancerous hematologic disorders that are not specifically discussed in this or another non-general policy, including known familial variant testing.

[back to top](#)

CRITERIA

It is the policy of health plans affiliated with Centene Corporation[®] that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

INHERITED THROMBOPHILIA

Factor V Leiden (*F5*) and Prothrombin (*F2*) Variant Analysis for Inherited Thrombophilia

- I. *F5* and *F2* variant analysis to confirm or establish a diagnosis of an inherited thrombophilia is considered **medically necessary** when:
 - A. The member/enrollee had a venous thromboembolism (VTE) that meets at least one of the following:
 1. Provoked by a [nonsurgical major transient risk factor](#), **OR**
 2. Provoked by pregnancy or postpartum, **OR**
 3. Provoked by combination oral contraceptive use, **OR**
 - B. The member/enrollee is planning to discontinue anticoagulation after venous thromboembolism (VTE), **AND**
 1. The member/enrollee has a personal history of one of the following:
 - a) Cerebral venous thrombosis, **OR**
 - b) Splanchnic venous thrombosis, **OR**
 - C. The member/enrollee has a minor provoking risk factor for VTE (e.g. immobility, minor injury, illness, infection), **AND**
 1. The member/enrollee has two [first- or second-degree relatives](#) with VTE, **OR**
 2. The member/enrollee meets both of the following:
 - a) At least one of the relatives had VTE under age 50, **AND**
 - b) The relative's thrombophilia status is unknown, **OR**

- D. The member/enrollee is a female planning a pregnancy, **AND**
 - 1. Has a [first- or second-degree relative](#) who is known to be homozygous for factor V Leiden, **OR**
 - 2. Has a [first- or second-degree relative](#) who is known to be a compound heterozygote for factor V Leiden and prothrombin (F2) mutation, **OR**
- E. The member/enrollee is receiving systemic cancer treatment, **AND**
 - 1. Does not have a personal history of VTE, **AND**
 - 2. Has a [first-degree relative](#) with VTE.
- II. Current evidence does not support *F5* and *F2* variant analysis to confirm or establish a diagnosis of an inherited thrombophilia for all other indications, including:
 - A. Fetal loss or adverse pregnancy outcomes (examples: placental abruption, fetal growth restriction, or preeclampsia).

[view rationale](#)

[back to top](#)

HEMOGLOBINOPATHIES

***HBA1/HBA2* and/or *HBB* Variant Analysis**

- I. *HBA1/HBA2* variant analysis and/or *HBB* variant analysis to confirm or establish a diagnosis of a hemoglobinopathy (alpha-thalassemia, beta-thalassemia, or sickle cell disease) is considered **medically necessary** when:
 - A. The member/employee's hematologic screening results (examples: MCV, MCH, CBC, hemoglobin electrophoresis, or dichlorophenol indophenol (DCIP)) are positive for a hemoglobinopathy, **OR**
 - B. The member/employee's hematologic screening results (examples: MCV, MCH, CBC, hemoglobin electrophoresis, or dichlorophenol indophenol (DCIP)) do not conclusively diagnose or rule out a hemoglobinopathy.
- II. Current evidence does not support *HBA1/HBA2* variant analysis and/or *HBB* variant analysis to confirm or establish a diagnosis of a hemoglobinopathy (alpha-thalassemia, beta-thalassemia, or sickle cell disease) for all other indications.

[view rationale](#)

[back to top](#)

HEMOPHILIA

Factor VIII (*F8*) and Factor IX (*F9*) Variant Analysis for Hemophilia A and B

- I. *F8* variant analysis and/or *F9* variant analysis to confirm or establish a diagnosis of hemophilia A or B is considered **medically necessary** when:
 - A. The member/employee has any of the following clinical features of hemophilia:
 1. Hemarthrosis (especially with mild or no antecedent trauma), **OR**
 2. Deep-muscle hematomas, **OR**
 3. Intracranial bleeding in the absence of major trauma, **OR**
 4. Neonatal cephalohematoma or intracranial bleeding, **OR**
 5. Prolonged oozing or renewed bleeding after initial bleeding stops following tooth extractions, mouth injury, or circumcision, **OR**
 6. Prolonged, delayed bleeding, or poor wound healing following surgery or trauma, **OR**
 7. Unexplained GI bleeding or hematuria, **OR**
 8. Heavy or prolonged menstrual bleeding (especially with onset at menarche), **OR**
 9. Prolonged nosebleeds, especially recurrent and bilateral, **OR**
 10. Excessive bruising (especially with firm, subcutaneous hematomas), **OR**
 - B. The member/employee has the following laboratory features:
 1. Normal platelet count, **AND**
 2. Prolonged activated partial thromboplastin time (aPTT), **AND**

3. Normal prothrombin time (PT).
- II. Current evidence does not support *F8* variant analysis and/or *F9* variant analysis to confirm or establish a diagnosis of hemophilia A or B for all other indications.

[view rationale](#)

[back to top](#)

VON WILLEBRAND DISEASE

VWF Variant Analysis

- I. Current evidence does not support *VWF* variant analysis to confirm or establish a diagnosis¹ of von-Willebrand disease for all indications.

¹ Diagnosis of von-Willebrand disease can be achieved by standard laboratory and biochemical testing.

[view rationale](#)

[back to top](#)

FANCONI ANEMIA

Fanconi Anemia Multigene Panel

- I. Multigene panel analysis to establish or confirm a genetic diagnosis of Fanconi anemia is considered **medically necessary** when:
 - A. The member/employee had a positive or inconclusive result via chromosome breakage analysis, **AND**
 - B. The member/employee displays at least one of the following:
 1. Prenatal and/or postnatal short stature, **OR**
 2. Abnormal skin pigmentation (e.g., café au lait macules, hyper- or hypopigmentation), **OR**
 3. Skeletal malformations (e.g., hypoplastic thumb, hypoplastic radius, vertebral anomalies), **OR**
 4. Microcephaly, **OR**

5. Ophthalmic anomalies, **OR**
 6. Genitourinary tract anomalies (e.g., horseshoe kidney, hypospadias, bicornuate uterus), **OR**
 7. Macrocytosis, **OR**
 8. Increased fetal hemoglobin (often precedes anemia), **OR**
 9. Cytopenia (especially thrombocytopenia, leukopenia and neutropenia), **OR**
 10. Progressive bone marrow failure, **OR**
 11. Adult-onset aplastic anemia, **OR**
 12. Myelodysplastic syndrome (MDS), **OR**
 13. Acute myelogenous leukemia (AML), **OR**
 14. Early-onset solid tumors (e.g., squamous cell carcinomas of the head and neck, esophagus, and vulva; cervical cancer; and liver tumors), **OR**
 15. Inordinate toxicities from chemotherapy or radiation.
- II. Current evidence does not support multigene panel analysis to establish or confirm a genetic diagnosis of Fanconi anemia for all other indications.

[view rationale](#)

[back to top](#)

OTHER COVERED HEMATOLOGIC CONDITIONS (NON-CANCEROUS)

Other Covered Hematologic Conditions (Non-Cancerous)

The following is a list of conditions that have a known genetic association. Due to their relative rareness, it may be appropriate to cover these genetic tests to establish or confirm a diagnosis.

- I. Genetic testing to establish or confirm one of the following hematologic conditions (non-cancerous) to guide management is considered **medically necessary** when the

member/employee demonstrates clinical features consistent with the disorder (the list is not meant to be comprehensive, see II below):

- A. [Atypical Hemolytic-Uremic Syndrome \(aHUS\)](#) (*C3, CD46, CFB, CFH, CFHR1, CFHR3, CFHR4, CFHR5, CFI, DGKE, THBD, VTN*)
 - B. [Complete Plasminogen Activator Inhibitor 1 Deficiency \(PAI-1\)](#) (*SERPINE1*)
 - C. [Diamond-Blackfan Anemia \(DBA\)](#) (*GATA17, RPL5, RPL9, RPL11, RPL15, RPL18, RPL26, RPL27, RPL31, RPL35, RPL35A, RPS7, RPS10, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27, RPS28, RPS29, TSR2*)
 - D. [Hereditary Spherocytosis](#) (*ANK1, EPB42, SLC4A1, SPTA1, SPTB*)
 - E. Factor VII Deficiency (*F7*)
 - F. Factor X Deficiency (*F10*)
 - G. Factor XI Deficiency (Hemophilia C) (*F11*)
 - H. Factor XII Deficiency (*F12*)
 - I. [Factor XIII Deficiency](#) (*F13A1*)
- II. Genetic testing to establish or confirm the diagnosis of all other non-cancerous hematologic conditions not specifically discussed within this or another medical policy will be evaluated by the criteria outlined in *General Approach to Genetic and Molecular Testing* (see policy for criteria).

NOTE: Clinical features for a specific disorder may be outlined in resources such as [GeneReviews](#), [OMIM](#), [National Library of Medicine](#), [Genetics Home Reference](#), or other scholarly source.

[back to top](#)

RATIONALE

Factor V Leiden (*F5*) and Prothrombin (*F2*) Variant Analysis for Inherited Thrombophilia

American Society of Hematology (ASH)

Evidence based guidelines published in 2023 provide recommendations for testing for thrombophilia, including hereditary and acquired types. These recommendations are helpful to guide anticoagulation treatment for patients with a personal or family history of venous thromboembolism (VTE).

The panel provided conditional recommendations for thrombophilia testing in the following scenarios:

- Patients with VTE associated with nonsurgical major transient or hormonal risk factors;
- Patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued;
- Pregnant women with a family history (first or second degree relative) of high-risk thrombophilia types;
- Patients with cancer receiving systemic therapy at low or intermediate risk of thrombosis and with a family history (first or second degree relative) of VTE (p. 7102-7104).

Recommendation 13 of the guideline says that “Thrombophilia testing may be considered if a patient has multiple family members with VTE, if the family member with VTE was young...A positive history is defined as having a first or second degree relative with VTE” (p. 7121).

The panel does not address or recommend testing for patients with cancer who have a personal history of VTE or who are at high risk of VTE (p. 7132). The panel also strongly recommends against thrombophilia testing in the general population before starting combined oral contraceptives (p. 7101).

American College of Obstetricians and Gynecologists (ACOG)

ACOG also published Practice Bulletin 197 (2018, reaffirmed 2022) on Inherited Thrombophilias in Pregnancy which states that “...screening for inherited thrombophilias is not recommended for women with a history of fetal loss or adverse pregnancy outcomes including abruption, preeclampsia, or fetal growth restriction because there is insufficient clinical evidence that antepartum prophylaxis with unfractionated heparin or low-molecular-weight-heparin prevents recurrence in these patients, and a causal association has not been established” (p. e23).

[back to top](#)

HBA1/HBA2 and/or HBB Variant Analysis

GeneReviews is an expert-authored review of current literature on a genetic disease, and goes through a rigorous editing and peer review process before being published online.

The recommended hemoglobinopathy evaluation testing for Alpha-Thalassemia, Beta-Thalassemia, and Sickle Cell Disease are as follows:

GeneReviews: Alpha-Thalassemia

Hemoglobin Bart hydrops fetalis (Hb Bart) syndrome, which is caused by deletion or inactivation of all four alpha globin genes, exhibits the following hematologic findings: severe macrocytic hypochromic anemia (in the absence of ABO or Rh blood group incompatibility), reticulocytosis (may be >60%), and peripheral blood smear with large, hypochromic red cells, severe anisopoikilocytosis, and numerous nucleated red cells. In addition, hemoglobin analysis will typically display decreased amounts or complete absence of hemoglobin A and increased amounts of Hb Bart.

Hemoglobin H disease (HbH disease), which is caused by deletion or inactivation of three alpha globin genes, exhibits the following hematologic findings: mild-to-moderate (rarely severe) microcytic hypochromic hemolytic anemia, moderate reticulocytosis (3%-6%), Peripheral blood smear with anisopoikilocytosis, and very rarely nucleated red blood cells, Red blood cell supravital stain showing HbH inclusions (β 4 tetramers) in 5%-80% of erythrocytes following incubation of fresh blood smears with 1% brilliant cresyl blue for one to three hours. In addition, hemoglobin analysis will typically display the presence of 0.8%-40% HbH and 60%-90% hemoglobin A.

GeneReviews: Beta-Thalassemia

Beta-Thalassemia typically displays the following hematologic findings: microcytic hypochromic anemia, absence of iron deficiency, anisopoikilocytosis with nucleated red blood cells on peripheral blood smear, and decreased or complete absence of hemoglobin A (HbA) and increased hemoglobin A2 (HbA2) and often hemoglobin F (HbF) on hemoglobin analysis.

GeneReviews: Sickle Cell Disease

Laboratory features of sickle cell disease include: normocytic anemia; sickle cells, nucleated red blood cells, target cells, and other abnormal red blood cells on peripheral blood smear; Howell-Jolly bodies indicate hyposplenism; presence of hemoglobin S (HbS) on a hemoglobin assay (e.g., high-performance liquid chromatography [HPLC], isoelectric focusing, cellulose acetate electrophoresis, citrate agar electrophoresis) with an absence or diminished amount of HbA.

Viprakasit V, Ekwattanakit S. Clinical classification, screening and diagnosis for thalassemia

Viprakasit and Ekwattanakit (2018) published a clinical classification, screening and diagnosis for thalassemia article that states:

In general, these mutation analyses would be critical for the confirmation of thalassemia diagnoses in only a few selected cases for whom the basic hematology and Hb analysis described could not provide a conclusive diagnosis. However, these molecular analyses would be indispensable in a program for the prevention and control of thalassemia syndromes because the mutation data would be required for genetic counseling, genetic risk calculation in the offspring, and prenatal and preimplantation genetic diagnosis. In addition, DNA analysis could help in predicting the clinical severity and guiding clinical management; milder b-globin mutations (b1-thal) usually are associated with milder phenotypes, as has been shown in HbE/b-thalassemia (p. 207).

[back to top](#)

Factor VIII (F8) and Factor IX (F9) Variant Analysis for Hemophilia A and B

GeneReviews is an expert-authored review of current literature on a genetic disease, and goes through a rigorous editing and peer review process before being published online.

The recommended hemoglobinopathy evaluation testing for Hemophilia A and Hemophilia B is as follows:

GeneReviews: Hemophilia A and Hemophilia B

Individuals with Hemophilia A (factor VIII deficiency) or Hemophilia B (factor IX deficiency) can exhibit the following clinical symptoms:

- Hemarthrosis, especially with mild or no antecedent trauma
- Deep-muscle hematomas
- Intracranial bleeding in the absence of major trauma
- Neonatal cephalohematoma or intracranial bleeding
- Prolonged oozing or renewed bleeding after initial bleeding stops following tooth extractions, mouth injury, or circumcision
- Prolonged or delayed bleeding or poor wound healing following surgery or trauma
- Unexplained GI bleeding or hematuria
- Heavy menstrual bleeding, especially with onset at menarche
- Prolonged nosebleeds, especially recurrent and bilateral
- Excessive bruising, especially with firm, subcutaneous hematomas

The following are laboratory findings in individuals with Hemophilia A or Hemophilia B:

- Normal platelet count

- Prolonged activated partial thromboplastin time (aPTT) (Note: in mild hemophilia B, aPTT may be normal or mildly prolonged)
- Normal prothrombin time (PT)

[back to top](#)

VWF Variant Analysis

Centers for Disease Control and Prevention (CDC)

Guidelines for diagnosis and management of von Willebrand disease (VWD) were developed by the CDC for practicing primary care and specialist clinicians - including family physicians, internists, obstetrician-gynecologists, pediatricians, and nurse-practitioners - as well as hematologists and laboratory medicine specialists, which included recommendations for laboratory tests to aid in the diagnosis of VWD, which notably do not include genetic testing.

[back to top](#)

Fanconi Anemia Multigene Panel

Fanconi Anemia Research Foundation

The Fanconi Anemia Research Foundation (2020) issued guidelines on diagnosis and management of the disease, which stated the following in regard to genetic testing:

If the results from the chromosome breakage test are positive, genetic testing should be performed to identify the specific FA-causing variants. Genetic testing enables accurate diagnosis and improves clinical care for individuals with anticipated genotype/phenotype manifestations and for relatives who are heterozygous carriers of FA gene variants that confer increased risk for malignancy (p. 28, additional testing methodologies pages 29-45).

GeneReviews: Fanconi Anemia

GeneReviews is an expert-authored review of current literature on a genetic disease, and goes through a rigorous editing and peer review process before being published online.

Fanconi anemia (FA) should be suspected in individuals with the following clinical and laboratory features.

Physical features (in ~75% of affected persons)

- Prenatal and/or postnatal short stature

- Abnormal skin pigmentation (e.g., café au lait macules, hypopigmentation)
- Skeletal malformations (e.g., hypoplastic thumb, hypoplastic radius)
- Microcephaly
- Ophthalmic anomalies
- Genitourinary tract anomalies

Laboratory findings

- Macrocytosis
- Increased fetal hemoglobin (often precedes anemia)
- Cytopenia (especially thrombocytopenia, leukopenia, and neutropenia)

Pathology findings

- Progressive bone marrow failure
- Adult-onset aplastic anemia
- Myelodysplastic syndrome (MDS)
- Acute myelogenous leukemia (AML)
- Early-onset solid tumors (e.g., squamous cell carcinomas of the head and neck, esophagus, and vulva; cervical cancer; liver tumors)
- Inordinate toxicities from chemotherapy or radiation

[back to top](#)

DEFINITIONS

1. **Close relatives** include first, second, and third degree blood relatives:
 - a. **First-degree relatives** are parents, siblings, and children
 - b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
 - c. **Third-degree relatives** are great grandparents, great aunts, great uncles, great grandchildren, and first cousins
2. **Nonsurgical major transient risk factors** include confinement to bed in the hospital with acute illness for at least 3 days, or a combination of minor transient risk factors such as admission of less than 3 days with acute illness or confinement to bed outside of

hospital for at least 3 days, or leg injury associated with decreased mobility for at least 3 days.

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	03/23	03/23
Semi-annual review. Updated title to reflect V1.2024 version. Overview, coding, reference-table, background and references updated. Throughout policy: replaced “coverage criteria” with “criteria. For Policy Reference Table; under Hemoglobinopathies: added “(GeneDx)””; and added “HBA1 Single Gene...””; added “(ARUP Laboratories)””; under Hemophilia: removed “F8 Sequencing Analysis” and added “(GeneDx)...””; removed “Deletion/Duplication Analysis...””; added “Full Gene Sequencing...””; under Glucose-6-Phosphate Dehydrogenase...” removed “Mutation Analysis...””; and added “Variant-Single Test...””; under von Willebrand Disease: removed “Sequencing Analysis...” and added “Gene Sequencing...””. For Other Related Policies: added “and Molecular”. For Criteria; under Hemoglobinopathies: added “variant analysis”; under Von-Willebrand Disease: added “/or”; under Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: added “and Molecular”. For Background and Rationale; under Known Familial Variant Analysis for Hematologic Conditions (non-cancerous): changed “inheritance patterns” to “genetic testing”.	10/23	10/23
Semi-annual review. Updated title to reflect V2.2024 version. In Known Familial Variant Analysis for Hematologic Conditions (non-cancerous) criteria, moved criteria to policy “Genetic Testing: General Approach to Genetic and Molecular Testing” to consolidate criteria for known familial variant tests. Minor rewording for clarity throughout. Coding, reference-table, background and references updated.	04/24	04/24
Semi-annual review. Updated title to reflect V1.2025. G6PD Variant Analysis: Streamlined portions of Background and Rationale section for brevity; Updated access date for online reference. Factor VIII (F8) and Factor IX (F9) Variant Analysis for Hemophilia A and B: Criteria renamed to "Factor VIII (F8) and Factor IX (F9) Variant Analysis for Hemophilia A and B". VWF Variant Analysis: Updated example test in Policy Reference Table; Updated GeneReviews copyright dates in Reference list. Factor V Leiden (F5) and Prothrombin (F2) Variant Analysis for Inherited Thrombophilia: Updated References to the 2023 ASH guidelines. Hemoglobinopathies - HBA1/HBA2 and/or HBB Variant Analysis: Updated GeneReviews copyright dates in Reference list.	11/24	

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Annual review. Policy renamed from Concert Genetic Testing: Hematologic Conditions (Non-Cancerous) to Concert Genetic Testing Hematology. Fanconi Anemia Multigene Panel: criteria moved from Concert Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay. Factor V Leiden (F5) and Prothrombin (F2) Variant Analysis for Inherited Thrombophilia: Criterion I.B.1.- clarified "personal history" rather than "history." "Investigational" policy statements changed to note that "current evidence does not support..." Coding table, rationale, background, and references updated.	11/25	12/25

REFERENCES

1. Middeldorp S, Nieuwlaar R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. *Blood Adv.* 2023;7(22):7101-7138. doi:10.1182/bloodadvances.2023010177
2. Tamary H, Dgany O. Alpha-Thalassemia. 2005 Nov 1 [Updated 2020 Oct 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1435/>
3. Langer, A. Beta-Thalassemia. 2000 Sep 28 [Updated 2024 February 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1426/>
4. Bender MA and Carlberg, K. Sickle Cell Disease. 2003 Sep 15 [Updated 2023 December 28]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1377/>
5. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy [published correction appears in Obstet Gynecol. 2018 (reaffirmed 2022) Oct;132(4):1069]. *Obstet Gynecol.* 2018;132(1):e18-e34. doi:10.1097/AOG.0000000000002703
6. Viprakasit V, Ekwattanakit S. Clinical Classification, Screening and Diagnosis for Thalassemia. *Hematol Oncol Clin North Am.* 2018;32(2):193-211. doi:10.1016/j.hoc.2017.11.006

7. Konkle BA, Nakaya Fletcher S. Hemophilia A. 2000 Sep 21 [Updated 2023 Jul 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1404/>
8. Konkle BA, Nakaya Fletcher S. Hemophilia B. 2000 Oct 2 [Updated 2023 Feb 9]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1495/>
9. von Willebrand Disease Guidelines: von Willebrand Disease (VWD) Diagnosis. Centers for Disease Control and Prevention website. July 7 2023. Accessed May 2, 2024. <https://www.cdc.gov/ncbddd/vwd/diagnosis.html>
10. MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: <https://medlineplus.gov/genetics/>.
11. Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1116/>
12. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide Web URL: <https://omim.org/>
13. Mehta PA, Tolar J. Fanconi Anemia. 2002 Feb 14 [Updated 2021 Jun 3]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1401/>
14. Sroka, I, Frohnmayr L,, et al., eds. Fanconi Anemia: Guidelines for Diagnosis and Management. Fifth Edition. Eugene, OR: Fanconi Anemia Research Foundation; 2020:21-33

[back to top](#)

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was

approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid member/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare member/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.